Page 294 - Haematologica Vol. 109 - July 2024

LETTER TO THE EDITOR
off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting. Clin Cancer Res. 2023;29(2):324-330.
13. La Rosa C, Diamond DJ. Triplex, a viral vectored CMV vaccine for transplant indications: clinical trial updates. Vaccine Insights. 2023;2(7):287-308.
14. Aldoss I, La Rosa C, Baden LR, et al. Poxvirus vectored cytomegalovirus vaccine to prevent cytomegalovirus viremia in transplant recipients: a phase 2, randomized clinical trial. Ann Intern Med. 2020;172(5):306-316.
15. Semmes EC, Chen JL, Goswami R, Burt TD, Permar SR, Fouda GG. Understanding early-life adaptive immunity to guide interventions for pediatric health. Front Immunol.
2020;11:595297.
16. Cesaro S, Crocchiolo R, Tridello G, et al. Comparable survival
using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. Bone Marrow Transplant. 2018;53(4):422-430.
17. Day EK, Carmichael AJ, ten Berge IJ, Waller EC, Sissons JG, Wills MR. Rapid CD8+ T cell repertoire focusing and selection of high-affinity clones into memory following primary infection with a persistent human virus: human cytomegalovirus. J Immunol. 2007;179(5):3203-3213.
Haematologica | 109 July 2024
2308